دورية أكاديمية
أعرض في EDS

Multiomics implicate gut microbiota in altered lipid and energy metabolism in Parkinson's disease.

التفاصيل البيبلوغرافية
العنوان: Multiomics implicate gut microbiota in altered lipid and energy metabolism in Parkinson's disease.
المؤلفون: Pereira PAB; Department of Neurology, Helsinki University Hospital, and Clinicum, University of Helsinki, Haartmaninkatu 4, 00290, Helsinki, Finland. pedro.pereira@helsinki.fi.; Institute of Biotechnology, DNA Sequencing and Genomics Laboratory, University of Helsinki, Viikinkaari 5D, 00014, Helsinki, Finland. pedro.pereira@helsinki.fi., Trivedi DK; Manchester Institute of Biotechnology, The University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK., Silverman J; College of Information Science and Technology, Department of Statistics, and Institute for Computational and Data Science, Penn State University, University Park, PA, USA.; Department of Medicine, Penn State University, Hershey, PA, USA., Duru IC; Institute of Biotechnology, DNA Sequencing and Genomics Laboratory, University of Helsinki, Viikinkaari 5D, 00014, Helsinki, Finland., Paulin L; Institute of Biotechnology, DNA Sequencing and Genomics Laboratory, University of Helsinki, Viikinkaari 5D, 00014, Helsinki, Finland., Auvinen P; Institute of Biotechnology, DNA Sequencing and Genomics Laboratory, University of Helsinki, Viikinkaari 5D, 00014, Helsinki, Finland., Scheperjans F; Department of Neurology, Helsinki University Hospital, and Clinicum, University of Helsinki, Haartmaninkatu 4, 00290, Helsinki, Finland. filip.scheperjans@hus.fi.
المصدر: NPJ Parkinson's disease [NPJ Parkinsons Dis] 2022 Apr 11; Vol. 8 (1), pp. 39. Date of Electronic Publication: 2022 Apr 11.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 101675390 Publication Model: Electronic Cited Medium: Print ISSN: 2373-8057 (Print) Linking ISSN: 23738057 NLM ISO Abbreviation: NPJ Parkinsons Dis Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [New York, NY] : Nature Publishing Group : Parkinson's Disease Foundation, [2015]-
مستخلص: We aimed to investigate the link between serum metabolites, gut bacterial community composition, and clinical variables in Parkinson's disease (PD) and healthy control subjects (HC). A total of 124 subjects were part of the study (63 PD patients and 61 HC subjects). 139 metabolite features were found to be predictive between the PD and Control groups. No associations were found between metabolite features and within-PD clinical variables. The results suggest alterations in serum metabolite profiles in PD, and the results of correlation analysis between metabolite features and microbiota suggest that several bacterial taxa are associated with altered lipid and energy metabolism in PD.
(© 2022. The Author(s).)
References: Skjærbæk, C., Knudsen, K., Horsager, J. & Borghammer, P. Gastrointestinal dysfunction in Parkinson’s disease. J. Clin. Med 10, 3 493 (2021). (PMID: 3357254710.3390/jcm10030493)
Scheperjans et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov. Disord. 30, 350–8 (2015). (PMID: 2547652910.1002/mds.26069)
Boertien, J. M., Pereira, P. A. B., Aho, V. T. E. & Scheperjans, F. Increasing comparability and utility of gut microbiome studies in Parkinson’s disease: a systematic review. J. Parkinsons Dis. 9, S297–S312 (2019). (PMID: 31498131683945310.3233/JPD-191711)
Cirstea et al. Microbiota composition and metabolism are associated with gut function in Parkinson’s disease. Mov. Disord. 35, 1208–1217 (2020). (PMID: 3235725810.1002/mds.28052)
Tan et al. Gut microbial ecosystem in parkinson disease: new clinicobiological insights from multi-omics. Ann. Neurol. 89, 546–559 (2021). (PMID: 3327448010.1002/ana.25982)
Aho et al. Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease. Mol. Neurodegener. 16, 6 (2021). (PMID: 33557896786924910.1186/s13024-021-00427-6)
Unger et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat. Disord. 32, 66–72 (2016). (PMID: 2759107410.1016/j.parkreldis.2016.08.019)
Hertel et al. Integrated analyses of microbiome and longitudinal metabolome data reveal microbial-host interactions on sulfur metabolism in Parkinson’s disease. Cell Rep. 29, 1767–1777.e8 (2019). (PMID: 31722195685672310.1016/j.celrep.2019.10.035)
Shin, C., Lim, Y., Lim, H. & Ahn, T. B. Plasma short-chain fatty acids in patients with Parkinson’s disease. Mov. Disord. 35, 1021–1027 (2020). (PMID: 3215494610.1002/mds.28016)
Vascellari et al. Gut microbiota and metabolome alterations associated with Parkinson’s disease. mSystems 5, 5 e00561–20 (2020). (PMID: 3293411710.1128/mSystems.00561-20)
Tan et al. Gut microbial ecosystem in Parkinson disease: new clinicobiological insights from multi-omics. Ann. Neurol. 89, 546–559 (2021). (PMID: 3327448010.1002/ana.25982)
Yan et al. Alterations of gut microbiota and metabolome with Parkinson’s disease. Micro. Pathog. 160, 105187 (2021). (PMID: 10.1016/j.micpath.2021.105187)
Mertsalmi et al. More than constipation—bowel symptoms in Parkinson’s disease and their connection to gut microbiota. Eur. J. Neurol. 24, 1375–1383 (2017). (PMID: 2889126210.1111/ene.13398)
Aho et al. Gut microbiota in Parkinson’s disease: temporal stability and relations to disease progression. EBioMedicine 44, 691–707 (2019). (PMID: 31221587660674410.1016/j.ebiom.2019.05.064)
Pereira et al. Oral and nasal microbiota in Parkinson’s disease. Parkinsonism Relat. Disord. 38, 61–67 (2017). (PMID: 2825962310.1016/j.parkreldis.2017.02.026)
Wishart et al. HMDB 4.0: the human metabolome database for 2018. Nucleic Acids Res 46, D608–D617 (2018). (PMID: 2914043510.1093/nar/gkx1089)
Sud et al. LMSD: LIPID MAPS structure database. Nucleic Acids Res. 35(Database issue), D527–32 (2007). (PMID: 1709893310.1093/nar/gkl838)
Sumner et al. Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics 3, 211–221 (2007). (PMID: 24039616377250510.1007/s11306-007-0082-2)
Sinclair et al. Metabolomics of sebum reveals lipid dysregulation in Parkinson’s disease. Nat. Commun. 12, 1592 (2021). (PMID: 33707447795256410.1038/s41467-021-21669-4)
Alecu, I. & Bennett, S. A. L. Dysregulated lipid metabolism and its role in α-synucleinopathy in Parkinson’s disease. Front Neurosci. 13, 328 (2019). (PMID: 31031582647029110.3389/fnins.2019.00328)
Lin, G., Wang, L., Marcogliese, P. C. & Bellen, H. J. Sphingolipids in the pathogenesis of Parkinson’s disease and Parkinsonism. Trends Endocrinol. Metab. 30, 106–117 (2019). (PMID: 3052846010.1016/j.tem.2018.11.003)
Hallett, P. J., Engelender, S. & Isacson, O. Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson’s disease. J. Neuroinflammation 16, 153 (2019). (PMID: 31331333664731710.1186/s12974-019-1532-2)
Xicoy, H., Wieringa, B. & Martens, G. J. M. The role of lipids in Parkinson’s disease. Cells 8, 27 (2019). (PMID: 635635310.3390/cells8010027)
Alessenko, A. V. & Albi, E. Exploring sphingolipid implications in neurodegeneration. Front Neurol. 11, 437 (2020). (PMID: 32528400725487710.3389/fneur.2020.00437)
Hu et al. Integrated metabolomics and proteomics analysis reveals plasma lipid metabolic disturbances in patients with Parkinson’s disease. Front Mol. Neurosci. 13, 80 (2020). (PMID: 32714143734425310.3389/fnmol.2020.00080)
van Kruining et al. Sphingolipids as prognostic biomarkers of neurodegeneration, neuroinflammation, and psychiatric diseases and their emerging role in lipidomic investigation methods. Adv. Drug Deliv. Rev. 159, 232–244 (2020). (PMID: 32360155766582910.1016/j.addr.2020.04.009)
Rodriguez-Cuenca, S., Pellegrinelli, V., Campbell, M., Oresic, M. & Vidal-Puig, A. Sphingolipids and glycerophospholipids—The “ying and yang” of lipotoxicity in metabolic diseases. Prog. Lipid Res. 66, 14–29 (2017). (PMID: 2810453210.1016/j.plipres.2017.01.002)
Saiki et al. Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson’s disease. Sci. Rep. 7, 7328 (2017). (PMID: 28779141554470810.1038/s41598-017-06767-y)
Rosario et al. Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson’s disease. Cell Rep. 34, 108807 (2021). (PMID: 3365738110.1016/j.celrep.2021.108807)
da Silva, R. P., Kelly, K. B., Al Rajabi, A. & Jacobs, R. L. Novel insights on interactions between folate and lipid metabolism. Biofactors 40, 277–83 (2014). (PMID: 2435311110.1002/biof.1154)
Shao et al. Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry. Mol. Neurodegener. 16, 4 (2021). (PMID: 33485385782515610.1186/s13024-021-00425-8)
Zhao et al. Potential biomarkers of Parkinson’s disease revealed by plasma metabolic profiling. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1081-1082, 101–108 (2018). (PMID: 10.1016/j.jchromb.2018.01.025)
Crooks et al. Carnitine levels and mutations in the SLC22A5 gene in Faroes patients with Parkinson’s disease. Neurosci. Lett. 675, 116–119 (2018). (PMID: 2961433110.1016/j.neulet.2018.03.064)
Jiménez-Jiménez et al. Cerebrospinal fluid carnitine levels in patients with Parkinson’s disease. J. Neurol. Sci. 145, 183–5 (1997). (PMID: 909404710.1016/S0022-510X(96)00259-6)
Utami, O. C., Kurniawati, Y., Diba, S. & Saleh, M. I. Correlation between serum lipid profile and acne vulgaris severity. J. Phys.: Conf. Ser. 1246, 012066 (2019).
Camera E, Picardo M. Lipids in serum and sebum, Pathogenesis and Treatment of Acne and Rosacea (Springer, 2013).
Rattray et al. Metabolic dysregulation in vitamin E and carnitine shuttle energy mechanisms associate with human frailty. Nat. Commun. 10, 5027 (2019). (PMID: 31690722683156510.1038/s41467-019-12716-2)
Fariss, M. W. & Zhang, J. G. Vitamin E therapy in Parkinson’s disease. Toxicology 189, 129–46 (2003). (PMID: 1282128810.1016/S0300-483X(03)00158-6)
Etminan, M., Gill, S. S. & Samii, A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson’s disease: a meta-analysis. Lancet Neurol. 4, 362–5 (2005). (PMID: 1590774010.1016/S1474-4422(05)70097-1)
Schirinzi et al. Dietary Vitamin E as a protective factor for Parkinson’s Disease: clinical and experimental evidence. Front Neurol. 10, 148 (2019). (PMID: 30863359639912110.3389/fneur.2019.00148)
Nikam, S., Nikam, P., Ahaley, S. K. & Sontakke, A. V. Oxidative stress in Parkinson’s disease. Indian J. Clin. Biochem 24, 98–101 (2009). (PMID: 23105815345346310.1007/s12291-009-0017-y)
Fernández-Irigoyen, J., Cartas-Cejudo, P., Iruarrizaga-Lejarreta, M. & Santamaría, E. Alteration in the cerebrospinal fluid lipidome in Parkinson’s disease: a post-mortem pilot study. Biomedicines 9, 491 (2021). (PMID: 33946950814670310.3390/biomedicines9050491)
Fanning, S., Selkoe, D. & Dettmer, U. Parkinson’s disease: proteinopathy or lipidopathy? NPJ Parkinsons Dis. 6, 3 (2020). (PMID: 31909184694197010.1038/s41531-019-0103-7)
Erskine et al. Lipids, lysosomes and mitochondria: insights into Lewy body formation from rare monogenic disorders. Acta Neuropathol. 141, 511–526 (2021). (PMID: 33515275795228910.1007/s00401-021-02266-7)
Lin et al. Phospholipase PLA2G6, a Parkinsonism-associated gene, affects Vps26 and Vps35, retromer function, and ceramide levels, similar to α-synuclein gain. Cell Metab. 28, 605–618.e6 (2018). (PMID: 2990997110.1016/j.cmet.2018.05.019)
Belarbi et al. Glycosphingolipids and neuroinflammation in Parkinson’s disease. Mol. Neurodegener. 15, 59 (2020). (PMID: 33069254756839410.1186/s13024-020-00408-1)
Zhu, M., Li, J. & Fink, A. L. The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. J. Biol. Chem. 278, 40186–97 (2003). (PMID: 1288577510.1074/jbc.M305326200)
Madine, J., Doig, A. J. & Middleton, D. A. A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers. Biochemistry 45, 5783–92 (2006). (PMID: 1666962210.1021/bi052151q)
Rawat, A., Langen, R. & Varkey, J. Membranes as modulators of amyloid protein misfolding and target of toxicity. Biochim Biophys. Acta Biomembr. 1860, 1863–1875 (2018). (PMID: 29702073620368010.1016/j.bbamem.2018.04.011)
Jo, E., McLaurin, J., Yip, C. M., St George-Hyslop, P. & Fraser, P. E. alpha-Synuclein membrane interactions and lipid specificity. J. Biol. Chem. 275, 34328–34 (2000). (PMID: 1091579010.1074/jbc.M004345200)
Broersen, K., van den Brink, D., Fraser, G., Goedert, M. & Davletov, B. Alpha-synuclein adopts an alpha-helical conformation in the presence of polyunsaturated fatty acids to hinder micelle formation. Biochemistry 45, 15610–6 (2006). (PMID: 1717608210.1021/bi061743l)
De Franceschi et al. Molecular insights into the interaction between alpha-synuclein and docosahexaenoic acid. J. Mol. Biol. 394, 94–107 (2009). (PMID: 1974749010.1016/j.jmb.2009.09.008)
De Franceschi et al. Structural and morphological characterization of aggregated species of α-synuclein induced by docosahexaenoic acid. J. Biol. Chem. 286, 22262–74 (2011). (PMID: 21527634312137210.1074/jbc.M110.202937)
Ludtmann et al. Monomeric alpha-synuclein exerts a physiological role on brain ATP synthase. J. Neurosci. 36, 10510–10521 (2016). (PMID: 27733604505942610.1523/JNEUROSCI.1659-16.2016)
Henzi, V., Reichling, D. B., Helm, S. W. & MacDermott, A. B. L-proline activates glutamate and glycine receptors in cultured rat dorsal horn neurons. Mol. Pharm. 41, 793–801 (1992).
Wu et al. Proline metabolism in the conceptus: implications for fetal growth and development. Amino Acids 35, 691–702 (2008). (PMID: 1833049710.1007/s00726-008-0052-7)
Ji, Y., Guo, Q., Yin, Y., Blachier, F. & Kong, X. Dietary proline supplementation alters colonic luminal microbiota and bacterial metabolite composition between days 45 and 70 of pregnancy in Huanjiang mini-pigs. J. Anim. Sci. Biotechnol. 9, 18 (2018). (PMID: 29423216578953410.1186/s40104-018-0233-5)
Dunn et al. Human serum metabolome (HUSERMET) consortium. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat. Protoc. 6, 1060–83 (2011). (PMID: 2172031910.1038/nprot.2011.335)
Begley et al. HUSERMET Consortium, Goodacre R, Kell DB. Development and performance of a gas chromatography-time-of-flight mass spectrometry analysis for large-scale nontargeted metabolomic studies of human serum. Anal. Chem. 81, 7038–46 (2009). (PMID: 1960684010.1021/ac9011599)
Chambers et al. A cross-platform toolkit for mass spectrometry and proteomics. Nat. Biotechnol. 30, 918–20 (2012). (PMID: 23051804347167410.1038/nbt.2377)
RStudio Team. RStudio: Integrated Development Environment for R. Boston, MA. Available from: http://www.rstudio.com/ (2015).
Smith, C. A., Want, E. J., O’Maille, G., Abagyan, R. & Siuzdak, G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal. Chem. 78, 779–87 (2006). (PMID: 1644805110.1021/ac051437y)
Domingo-Almenara et al. eRah: a computational tool integrating spectral deconvolution and alignment with quantification and identification of metabolites in GC/MS-based metabolomics. Anal. Chem. 88, 9821–9829 (2016). (PMID: 2758400110.1021/acs.analchem.6b02927)
Duan, K. B., Rajapakse, J. C., Wang, H. & Azuaje, F. Multiple SVM-RFE for gene selection in cancer classification with expression data. IEEE Trans. Nanobioscience 4, 228–34 (2005). (PMID: 1622068610.1109/TNB.2005.853657)
Kurlowicz, L. & Greenberg, S. A. The geriatric depression scale (GDS). Am. J. Nurs. 107, 67–68 (2007). (PMID: 10.1097/01.NAJ.0000292207.37066.2f)
Ombaugh, T. N., McDowell, I., Kristjansson, B. & Hubley, A. M. Mini-mental state examination (MMSE) and the modified MMSE (3MS): a psychometric comparison and normative data. Psychological Assess. 8, 48–59 (1996). (PMID: 10.1037/1040-3590.8.1.48)
Chaudhuri, K. R. & Martinez-Martin, P. Quantitation of non-motor symptoms in Parkinson’s disease. Eur. J. Neurol. 15(Suppl 2), 2–7 (2008). (PMID: 1870273610.1111/j.1468-1331.2008.02212.x)
Stiasny-Kolster et al. The REM sleep behavior disorder screening questionnaire-a new diagnostic instrument. Mov. Disord. 22, 2386–93 (2007). (PMID: 1789433710.1002/mds.21740)
Rome Foundation. Guidelines-Rome III diagnostic criteria for functional gastrointestinal disorders. J. Gastrointestin Liver Dis. 15, 307–12 (2006).
Agachan, F., Chen, T., Pfeifer, J., Reissman, P. & Wexner, S. D. A constipation scoring system to simplify evaluation and management of constipated patients. Dis. Colon Rectum 39, 681–5 (1996). (PMID: 864695710.1007/BF02056950)
Lloret et al. Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson’s disease. Mov. Disord. 22, 107–11 (2007). (PMID: 10.1002/mds.21152)
Lam et al. Simple clinical tests may predict severe oropharyngeal dysphagia in Parkinson’s disease. Mov. Disord. 22, 640–4 (2007). (PMID: 1726607510.1002/mds.21362)
Li et al. Predicting network activity from high throughput metabolomics. PLoS Comput. Biol. 9, e1003123 (2013). (PMID: 23861661370169710.1371/journal.pcbi.1003123)
Chong, J. & Xia, J. MetaboAnalystR: an R package for flexible and reproducible analysis of metabolomics data. Bioinformatics 34, 4313–4314 (2018). (PMID: 29955821628912610.1093/bioinformatics/bty528)
Silverman, J. D., Roche, K., Holmes, Z. C., David, L. A. & Mukherjee, S. Bayesian Multinomial Logistic Normal Models through Marginally Latent Matrix-T Processes. J. Mach. Learn. Res. 23, 1–42 (2022).
R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/ (2020).
Aitchison, J. The Statistical Analysis of Compositional Data. (Monographs on statistics and applied probability, Chapman and Hall, London, New York, 1986). (PMID: 10.1007/978-94-009-4109-0)
Friedman, J. & Alm, E. J. Inferring correlation networks from genomic survey data. PLoS Comput. Biol. 8, e1002687 (2012). (PMID: 23028285344797610.1371/journal.pcbi.1002687)
Shannon et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–504 (2003). (PMID: 1459765840376910.1101/gr.1239303)
Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30 (2000). (PMID: 1059217310240910.1093/nar/28.1.27)
معلومات مُعتمدة: 295724, 310835 Academy of Finland (Suomen Akatemia)
تواريخ الأحداث: Date Created: 20220412 Latest Revision: 20221024
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9001728
DOI: 10.1038/s41531-022-00300-3
PMID: 35411052
قاعدة البيانات: MEDLINE
الوصف
تدمد:2373-8057
DOI:10.1038/s41531-022-00300-3